Clinical Trial Update: Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment [NA]

View source ↗

Summary

A clinical trial is evaluating the telemonitoring platform CUREETY TECHCARE versus standard of care for patients with metastatic triple-negative breast cancer i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Snippet

Sponsor: UNICANCER | Conditions: Metastatic Triple-Negative Breast Carcinoma | NA | Status: RECRUITING